共 29 条
Serologically assessed heat shock protein 47 is related to fibrosis stage in early compensated alcohol-related liver disease
被引:5
|作者:
Lonsmann, Ida
[1
,3
,5
]
Gudmann, Natasja Staehr
[1
]
Manon-Jensen, Tina
[1
]
Thiele, Maja
[2
,3
]
Moreno, Ydalina Maria
[1
]
Langholm, Lasse Locke
[1
]
Nielsen, Mette Juul
[1
]
Detlefsen, Sonke
[3
,4
]
Karsdal, Morten Asser
[1
]
Krag, Aleksander Ahm
[2
,3
]
Leeming, Diana Julie
[1
]
机构:
[1] Nord Biosci A S, Biomarkers & Res, Herlev, Denmark
[2] Odense Univ Hosp, Dept Gastroenterol & Hepatol, Odense, Denmark
[3] Univ Southern Denmark, Fac Hlth Sci, Dept Clin Res, Odense, Denmark
[4] Odense Univ Hosp, Dept Pathol, Odense, Denmark
[5] Nord Biosci, Biomarkers & Res, Herlev Hovedgade 205-207, DK-2730 Herlev, Denmark
基金:
欧盟地平线“2020”;
关键词:
Non -invasive biomarker;
Collagen chaperone;
Fibrosis assessment;
Biomarker development;
Biomarker validation;
MOLECULAR CHAPERONE HSP47;
COLLAGEN;
EXPRESSION;
TISSUE;
HEAT-SHOCK-PROTEIN-47;
INVOLVEMENT;
VALIDATION;
GROWTH;
GENE;
D O I:
10.1016/j.clinbiochem.2021.12.008
中图分类号:
R446 [实验室诊断];
R-33 [实验医学、医学实验];
学科分类号:
1001 ;
摘要:
Background and aims: Heat shock protein (HSP)47 is a collagen-specific chaperone, essential for the correct formation of fibrillar procollagens. Collagen accumulation in the extracellular matrix (ECM) is a hallmark of fibrogenesis. The expression of HSP47 is proportional to the rate of collagen formation. Thus, HSP47 is a potential drug target for fibrotic diseases. We hypothesized that a C-terminal fragment of HSP47 (HSP47-C) could be quantified serologically and related to liver fibrosis stage. For this, a novel competitive enzyme-linked immunosorbent assay (ELISA) was developed. Method: An ELISA employing a monoclonal antibody targeting HSP47-C was developed and technically validated. The assay was evaluated in serum from a cross-sectional biopsy-controlled study of 281 patients with alcohol-related liver disease (ALD) and 50 gender, age and BMI matched healthy controls (HC). All liver biopsies from ALD patients were scored by one pathologist according to fibrosis stage (F0-4). Results: The HSP47-C assay was technically robust and specific for the target sequence. HSP47-C was 39% higher in ALD patients (median 17.7 ng/mL, IQR 12.4-24.0 ng/mL) compared to HC (median 12.7 ng/mL, IQR 9.4-15.7 ng/mL, p < 0.0001). In addition, HSP47-C was elevated in patients with severe fibrosis (F3-4, median 22.8 ng/mL, IQR 17.5-33.3 ng/mL) compared to none-to-moderate fibrosis (F0-2, median 16.5 ng/mL, IQR 11.8-22.5 ng/mL) with an AUROC of 0.72 (p < 0.0001). HSP47-C also correlated with other liver disease parameters, albumin, bilirubin and aspartate transaminase. Conclusion: We developed a competitive ELISA for serological detection of HSP47-C. The study supports HSP47 as a potential marker of liver fibrosis in ALD.
引用
收藏
页码:36 / 43
页数:8
相关论文